Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study - 14/02/14
Abstract |
Background |
Recent case-control studies observed an increased prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with psoriasis, which is relevant in selecting optimal psoriasis treatment.
Objective |
We sought to compare the prevalence of NAFLD in people with psoriasis and those without psoriasis.
Methods |
This large prospective population-based cohort study (part of the Rotterdam Study) enrolled elderly participants (>55 years). NAFLD was diagnosed as fatty liver on ultrasonography in the absence of other liver diseases. Participants with psoriasis were identified using a validated algorithm. Multivariable logistic regression model was used to assess whether psoriasis was associated with NAFLD after adjusting for demographic, lifestyle characteristics, and laboratory findings.
Results |
In total, 2292 participants were included (mean age 76.2 ± 6.0 years; 58.7% female; mean body mass index 27.4 ± 4.2kg/m2) of whom 118 (5.1%) had psoriasis. The prevalence of NAFLD was 46.2% in patients with psoriasis compared with 33.3% for the reference group without psoriasis (P = .005). Psoriasis was significantly associated with NAFLD; after adjustment for alcohol consumption, pack-years and smoking status, presence of metabolic syndrome, and alanine aminotransferase, psoriasis remained a significant predictor of NAFLD (adjusted odds ratio 1.7, 95% confidence interval 1.1-2.6).
Limitations |
This was a cross-sectional study.
Conclusion |
Elderly participants with psoriasis are 70% more likely to have NAFLD than those without psoriasis independent of common NAFLD risk factors.
Le texte complet de cet article est disponible en PDF.Key words : comorbidity, liver disease, metabolic syndrome, nonalcoholic fatty liver disease, psoriasis
Abbreviations used : ALT, BMI, CI, NAFLD, OR, PASI
Plan
| The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture, and Science; the Ministry of Health, Welfare, and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. This study was financially supported by the Foundation for Liver Research (SLO), Rotterdam, The Netherlands. |
|
| Disclosure: Dr Nijsten served as speaker, consultant, and investigator for Abbvie, Janssen, Pfizer, Galderma, Celgene, and Leo Pharma. Dr van der Voort, Dr Koehler, Dr Dowlatshahi, Dr Hofman, Dr Stricker, Dr Janssen, and Dr Schouten have no conflicts of interest to declare. |
Vol 70 - N° 3
P. 517-524 - mars 2014 Retour au numéro
Article précédent
- Psoriasis prevalence among adults in the United States
- Tara D. Rachakonda, Clayton W. Schupp, April W. Armstrong
- Long-term durability and dose escalation patterns in infliximab therapy for psoriasis
- Adam J. Luber, Cindy L. Tsui, Gillian M. Heinecke, Mark G. Lebwohl, Jacob O. Levitt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?